Key result
Ticlopidine reduced the annual recurrence rate of cerebral thrombosis compared to aspirin and no treatment, while anticoagulants reduced cerebral embolism recurrence.
Why the study?
Do antiplatelet or anticoagulant agents reduce stroke recurrence in patients with first-ever completed stroke?
Observational (n=311)
Do antiplatelet or anticoagulant agents reduce stroke recurrence in patients with first-ever completed stroke?
Ticlopidine is effective for secondary prevention of cerebral thrombosis, while anticoagulants are effective for secondary prevention of cerebral embolism.
Answers are grounded in this paper and cite their sources.
May support subtype-specific secondary prevention; leaves open need for randomized confirmation in contemporary cohorts.
completed strokeの二次予防を抗血小板薬のaspirin (ASA), ticlopidine (TP), 抗凝固薬のwarfarin, bucolomeの使用の有無より検討した.対象者は初発の脳血栓症252名 (男154名, 女98名), 脳塞栓症59名 (男38名, 女21名), 観察開始年齢は男64.4±12.9歳, 女67.5±11.1歳, 観察期間は男1,410.8±1,316.6日, 女1,526.5±1,344.6日であった.脳血栓症では年間再発率はASA群5.28%, TP群2.29%, 非服用群6.54%で, TP群はASA群, 非服用群に比べ再発が有意に少なかった (危険率5%).脳塞栓症では年間再発率はASA群11.16%, TP群19.31%, warfarin群4.13%, bucolome群 (warfarinと併用) 0%, 非服用群24.88%で, 抗凝固薬群 (warfarin, bucolome) が抗血小板薬群 (ASA, TP), 非服用群に比べ再発が有意に少なかった (危険率1%).脳出血の発症数と年間発症率は, ASA群1名, 0.67%, TP群1名, 0.13%, 抗凝固薬群1名, 0.92%, 無治療患者群2名, 0.69%であった.
No takes yet. Share an insight, caveat, or question.
恒彦 et al. (1995) conducted an observational in First-ever completed stroke (cerebral thrombosis and embolism) (n=311). Antiplatelet agents (aspirin, ticlopidine) and anticoagulants (warfarin, bucolome) vs. No treatment was evaluated on Annual recurrence rate of stroke (p=<0.05). Ticlopidine reduced the annual recurrence rate of cerebral thrombosis compared to aspirin and no treatment, while anticoagulants reduced cerebral embolism recurrence.
Synapse has enriched 10 related papers. Consider them for comparative context: